rethinkPeptides Search
Menu
RethinkPeptides

Next-Gen Obesity Peptides

Explore peptide research and guides on next-gen obesity peptides.

Next-Gen Obesity Peptides

Beyond Triple Agonists: Quadruple Targets?

After retatrutide's 28.7% weight loss, researchers are exploring quadruple receptor agonists targeting GLP-1, GIP, glucagon, and additional pathways like IGF-1.

Next-Gen Obesity Peptides

Danuglipron: Pfizer's Oral GLP-1 That Didn't Make It

Danuglipron showed up to 13% weight loss in Phase 2b but was discontinued in 2025 after liver injury signal and 50%+ dropout rates. Full clinical data review.